GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xylo Technologies Ltd (NAS:XYLO) » Definitions » Intrinsic Value: Projected FCF

Xylo Technologies (Xylo Technologies) Intrinsic Value: Projected FCF : $-42.04 (As of Jun. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Xylo Technologies Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-06), Xylo Technologies's Intrinsic Value: Projected FCF is $-42.04. The stock price of Xylo Technologies is $1.9424. Therefore, Xylo Technologies's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Xylo Technologies's Intrinsic Value: Projected FCF or its related term are showing as below:

XYLO's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.685
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Xylo Technologies Intrinsic Value: Projected FCF Historical Data

The historical data trend for Xylo Technologies's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xylo Technologies Intrinsic Value: Projected FCF Chart

Xylo Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -201.73 -88.29 -14.16 -17.19 -42.04

Xylo Technologies Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.16 - -17.19 - -42.04

Competitive Comparison of Xylo Technologies's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Xylo Technologies's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xylo Technologies's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xylo Technologies's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Xylo Technologies's Price-to-Projected-FCF falls into.



Xylo Technologies Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Xylo Technologies's Free Cash Flow(6 year avg) = $-6.04.

Xylo Technologies's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)*0.8)/Shares Outstanding (Diluted Average)
=(14.862653310476*-6.0378571428571+23.576*0.8)/1.686
=-42.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xylo Technologies  (NAS:XYLO) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Xylo Technologies's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=1.9424/-42.039013910122
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xylo Technologies Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Xylo Technologies's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Xylo Technologies (Xylo Technologies) Business Description

Traded in Other Exchanges
Address
10 Hanechoshet Street, 4th Floor, Tel Aviv, ISR, 6971072
Medigus Ltd is an Israel-based medical device company. It is engaged in the development, manufacturing, and marketing of surgical endostaplers and direct vision systems for minimally invasive medical procedures. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incisionless treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company also develops a range of micro video cameras under the micro ScoutCam portfolio of products. It operates in five segments: Medical, E-Commerce, Online, Electric Vehicles, and Corporate. The company's geographical segments include the United States, United Kingdom, Germany, Israel, China, and Others.